Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) is a slow growing B-cell malignancy that remains incurable. Most patients with CLL relapse become refractory to treatment. Several newly approved agents have promising clinical activity in CLL, including "difficult-to-treat" populations. Educating oncology healthcare professionals about choosing between these new therapeutic options to treat patients with CLL will contribute to the effective management of this condition and could help improve patient outcomes.
Evaluate patient and disease-related factors used to diagnose and risk-stratify patients with CLL in order to select appropriate treatment strategies; apply shared decision-making techniques when treating patients with CLL; define strategies to monitor and manage patients during "watch and wait" protocols and to identify disease progression
- 1.50 AMA PRA Category 1 Credit(s)™